somapacitan-beco injection, A once-weekly growth hormone injection providing 313 more injection-free days per year compared to daily growth hormone therapy.
Sogroya® (somapacitan-beco) is a long-acting growth hormone analog from Novo Nordisk. It binds to albumin in the bloodstream to extend its half-life, allowing for once-weekly dosing. Compared to daily GH therapy, Sogroya® delivers 313 more injection-free days per year.
Switching from daily to once-weekly Sogroya® means patients receive only 52 injections per year instead of 365, significantly reducing treatment burden.
More Injection-Free Days
Per year vs. daily therapy
Contact our team to learn about once-weekly growth hormone therapy and whether Sogroya® is right for you or your patient.